Pulled from Benzinga Pro data, Globus Medical (NYSE:GMED) posted Q1 earnings of $38.08 million, an increase from Q4 of 152.11%. Sales dropped to $230.55 million, a 7.79% decrease between quarters. In Q4, Globus Medical brought in $250.02 million in sales but only earned $15.11 million.
What Is Return On Invested Capital?
Earnings data without context is not clear and can difficult to base trading decisions on. Return on Invested Capital (ROIC) helps to filter signal from noise by measuring yearly pre-tax profit relative to invested capital by a business. Generally, a higher ROIC suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Globus Medical posted an ROIC of 2.73%.
It is important to keep in mind that ROIC evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.
Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q1, Globus Medical posted an ROIC of 2.73%.
Keep in mind, while ROIC is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.
For Globus Medical, the positive return on invested capital ratio of 2.73% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.
Globus Medical reported Q1 earnings per share at $0.42/share, which did not meet analyst predictions of $0.47/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.